Actelion receives Canada approval for Uptravi

Tue Jan 26, 2016 1:24am EST
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

ZURICH (Reuters) - Actelion Ltd ATLN.VX, Europe's biggest biotech firm, said on Tuesday that Health Canada had granted a notice of compliance for Uptravi, a new pulmonary arterial hypertension medicine.

The approval is "a major milestone", Chief Executive Jean-Paul Clozel said in a statement, adding that the company is working to make the drug available to patients in Canada "as soon as possible".

Analysts have said Uptravi could reap more than $1 billion in global sales annually at its peak.

(Reporting by Joshua Franklin; editing by Brenna Hughes Neghaiwi)

 
A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015.    REUTERS/Arnd Wiegmann